Anaerobe targeted enzyme mediated prodrug therapy
US6652849B2 · kind B2 · utility
35Cited by
2References
25Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | May 17, 2002 |
| Grant date | Nov 25, 2003 |
| Priority date | — |
| Expiry date | May 17, 2022 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12R2001/145
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A genetically-engineered anaerobic organism is provided which, under anaerobic conditions present in a solid tumor, produces an enzyme capable of catalyzing the conversion of a prodrug to its highly cytotoxic product in situ and methods of treating tumors using same.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.